# Alzheimer's Advances: Spotlight on Vaccine Progress Newsy: Alzheimer’s News Weekly Published: 2025-11-17T14:30:00.635Z Source: https://newsyai.com/edition/f74a21e4-8507-49e6-a4d6-d92ed50b9fe6 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- # The Alzheimer’s Treatment Briefing Coverage period: November 10–17, 2025 (U.S.) Note up front: It was a quiet week for drug approvals and late‑stage readouts, but a few fresh signals could shape what gets treated, who can benefit, and how we find the right patients sooner. ## Top stories (ranked) 1) Early Alzheimer’s vaccine program moves into the spotlight at December meeting - What’s new - Researchers announced they will share Phase 1 results and the Phase 2 plan for AV‑1959R, an Aβ “epitope” vaccine, at the CTAD 2025 conference on December 4. The goal is to train the immune system to make its own antibodies against toxic amyloid, with future use aimed at prevention or very early treatment. This week’s update confirms the session and highlights the secondary‑prevention focus. ([prnewswire.com](https://www.prnewswire.com/news-releases/nuravax-institute-for-molecular-medicine-to-present-phase-1-results-and-phase-2-design-of-alzheimers-vaccine-av-1959r-at-ctad-2025-302495153.html?utm_source=openai)) - Why this matters - If active immunization proves safe and effective, it could become a lower‑cost, easier alternative to frequent infusions or injections, especially for people caught very early by blood tests. It’s still early days—no Phase 3 data yet—but the direction is important as the field pushes upstream to prevent disease before major memory loss. 2) Largest analysis of Alzheimer’s brain tissue from Black Americans points to a shared drug target - What’s new - A new analysis of donated brain tissue from African American individuals with Alzheimer’s identified 400+ differently expressed genes; notably, ADAMTS2 stood out and has also been implicated in people of European ancestry. The overlap suggests some biology—and potential targets—may be shared across groups. Published November 11. ([medscape.com](https://www.medscape.com/viewarticle/new-insight-alzheimers-disease-african-americans-2025a1000v7a?utm_source=openai)) - Why this matters - Medicines must work for everyone. Finding a target that shows up across populations improves the odds that future drugs could help a wider range of patients and supports more inclusive trials and biomarker development. 3) Income ties to dementia risk factors underscore “treat the whole person” alongside drugs - What’s new - A Neurology study (published November 12) found that people with lower incomes were more likely to have changeable risk factors tied to dementia—hearing loss, high blood pressure, depression, inactivity, vision loss, and social isolation. Even after adjusting for income, some risks remained higher in historically underrepresented groups. ([newswise.com](https://www.newswise.com/articles/new-study-reveals-how-your-income-may-shape-your-risk-of-dementia?utm_source=openai)) - Why this matters - Disease‑slowing drugs are one piece of the puzzle. Addressing hearing and vision problems, blood pressure, activity, and loneliness can be “treatments” too—often cheaper, safer, and immediately actionable, and they may boost the benefits of medicines. 4) “Digital twins” for Alzheimer’s: a new preprint shows more precise forecasts of decline - What’s new - A November 12 preprint describes a personalized, data‑driven model that predicts an individual’s brain shrinkage patterns and future thinking changes better than standard tools, using MRI/PET and clinical data. This could help pick the right patients and timing for therapies. ([arxiv.org](https://arxiv.org/abs/2511.08847?utm_source=openai)) - Why this matters - Current drugs work best at the earliest stages. Smarter forecasting could shorten time to treatment, improve trial design, and help clinics plan monitoring (for example, when to scan, when to pause or continue therapy). ## Quick takeaways for patients and caregivers this week - Ask about prevention basics during treatment talks. Hearing aids, blood pressure control, regular movement, and staying socially connected are not “nice to haves”—they’re evidence‑linked ways to reduce risk and may complement medications. Bring these up at your next visit. ([newswise.com](https://www.newswise.com/articles/new-study-reveals-how-your-income-may-shape-your-risk-of-dementia?utm_source=openai)) - Inclusive research is getting better. New genetic findings in underrepresented groups are helping ensure tomorrow’s treatments fit more people. If you’re open to research, ask local centers about studies that welcome diverse participants. ([medscape.com](https://www.medscape.com/viewarticle/new-insight-alzheimers-disease-african-americans-2025a1000v7a?utm_source=openai)) - Keep an eye on December data drops. The Alzheimer’s vaccine session at CTAD could preview a future where prevention becomes more practical and affordable, but results will need to show clear benefits and safety. ([prnewswire.com](https://www.prnewswire.com/news-releases/nuravax-institute-for-molecular-medicine-to-present-phase-1-results-and-phase-2-design-of-alzheimers-vaccine-av-1959r-at-ctad-2025-302495153.html?utm_source=openai)) ## In case you missed it recently (context for access and operations) - Home injections for Leqembi (weekly “IQLIK” autoinjector) are already FDA‑cleared for maintenance after 18 months of IV therapy, which may ease clinic bottlenecks; programs are still ramping up site by site. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/?utm_source=openai)) If you want, I can deliver a rapid, plain‑English digest from CTAD (Dec 1–4) focused strictly on what changes for patient care.